Curis (CRIS) to Release Earnings on Tuesday

Curis (NASDAQ:CRIS) will be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect Curis to post earnings of ($1.94) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.91) by ($0.12). Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. The firm had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.95 million. During the same quarter in the prior year, the firm posted ($2.40) EPS. On average, analysts expect Curis to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Curis Stock Performance

Shares of CRIS opened at $16.36 on Friday. Curis has a fifty-two week low of $3.80 and a fifty-two week high of $19.60. The firm has a 50-day simple moving average of $12.69 and a 200-day simple moving average of $10.80. The company has a market capitalization of $96.36 million, a price-to-earnings ratio of -1.83 and a beta of 3.59.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their target price on shares of Curis from $51.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, February 9th.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.